No Data
No Data
Atlantic Coastal Acquisition Corp. Receives Expected Nasdaq Delisting Determination
NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Atlantic Coastal Acquisition Corp. (NASDAQ:ACAH) (the "Company"), a special purpose acquisition company, announced today that on February 14, 2024, the
Abpro Announces Filing of Registration Statement on Form S-4 in Connection With Business Combination Agreement With Atlantic Coastal Acquisition Corp. II
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with
Atlantic Coastal Acquisition Corp. II Announces Extension of Business Combination Period and Additional Contribution to Trust Account
Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition corporation, announced that Atlantic Coastal...
Abpro to Become Publicly Traded via Merger With Atlantic Coastal Acquisition Corp. II
Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725
Press Release: IMPORTANT: Atlantic Coastal Acquisition Corp. Files Definitive Proxy Statement in Connection With Plan to Extend the Amount of Time the Company Has to Consummate a Business Combination
IMPORTANT: Atlantic Coastal Acquisition Corp. Files Definitive Proxy Statement in Connection with Plan to Extend the Amount of Time the Company has to Consummate a Business Combination PR Newswire N
Press Release: Atlantic Coastal Acquisition Corp. Announces Plans to Extend Deadline to Complete Initial Business Combination.
Atlantic Coastal Acquisition Corp. Announces Plans to Extend Deadline to Complete Initial Business Combination. PR Newswire NEW YORK, Aug. 25, 2023 The Company Also Received a Notice of Non-complia
No Data